LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

Inicio・Lista de Acciones・uniQure NV

uniQure NV

Cerrado

26.7 -4.91

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

26.23

Máximo

28.08

Métricas clave
By Trading Economics
Ingresos	-16M -54M
Ventas	-2M 3.6M
BPA	-0.73
Margen de beneficios	-1,502.948
Empleados	221
EBITDA	13M -36M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+49.22% upside

Dividendos
By Dow Jones
Próximas Ganancias	28 jul 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	476M 1.8B
Apertura anterior	31.61
Cierre anterior	26.7

uniQure NV Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

2 mar 2026, 13:13 UTC

Principales Movimientos del Mercado

UniQure Down in Premarket as FDA Says Huntington's Gene-Therapy Data Falls Short

9 ene 2026, 15:14 UTC

Principales Movimientos del Mercado

UniQure Climbs on Scheduling FDA Meeting for Huntington's Disease Treatment

3 nov 2025, 13:34 UTC

Principales Movimientos del Mercado

UniQure Shares Sink After Negative FDA Response to Huntington's Disease Treatment

24 sept 2025, 18:51 UTC

Ganancias

These Stocks Are Moving the Most Today: Alibaba, Micron, Lithium Americas, Freeport-McMoRan, uniQure, and More -- Barrons.com

Comparación entre iguales

Cambio de precio

uniQure NV previsión

Precio Objetivo

By TipRanks

49.22% repunte

Estimación a 12 Meses

Media 42.11 USD 49.22%

Máximo 95 USD

Mínimo 14 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para uniQure NV Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

Comprar

Mantener

Vender

De acuerdo con 10 analistas que ofrecen calificaciones bursátiles a para uniQure NV Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de uniQure NV

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.